Amyloid Clearance by Aducanumab Cuts Tau Pathology in Treated Brain Regions
A rare autopsy case shows brain regions cleared of amyloid after aducanumab treatment had less tau pathology and slower atrophy.
Summary
Researchers at the University of Pennsylvania examined the brain of a man in his 50s with mild cognitive impairment and a TREM2 genetic risk variant who received aducanumab — an amyloid-targeting Alzheimer's drug — for 4.5 years before dying four years after his final dose. At autopsy, brain regions where amyloid had been effectively cleared showed notably less tau pathology and slower cortical thinning compared to untreated controls. Intriguingly, amyloid clearance was uneven: gyral crests (the raised folds of the brain) cleared more thoroughly, while sulcal depths (the valleys) retained higher amyloid loads and showed tau damage similar to untreated patients. The findings suggest that truly extensive amyloid removal may be necessary to achieve downstream neuroprotective benefits, and that the geometry of the brain influences how well the drug works.
Detailed Summary
Amyloid-targeting therapies like aducanumab have generated intense debate: they reduce amyloid plaques on brain scans, but whether that translates into genuine neuroprotection has been unclear. This landmark autopsy case offers the first direct window into what amyloid clearance actually looks like in brain tissue — and whether it matters for downstream damage.
Researchers studied a man in his 50s carrying the p.R47H TREM2 variant, a known Alzheimer's risk gene, who had mild cognitive impairment and enrolled in an aducanumab clinical trial. He received 30 doses totaling 280 mg/kg over 4.5 years, then died four years after his final treatment. His brain was compared at autopsy to 14 untreated controls matched for age and TREM2 status.
The results revealed a striking spatial pattern. Brain regions at gyral crests — the raised ridges of cortical folds — showed very low residual amyloid, reduced tau pathology, and significantly slower longitudinal cortical atrophy on MRI (β = -0.50; p < .001). In contrast, sulcal depths — the valleys between folds — retained high amyloid levels and had tau burdens comparable to untreated patients. This suggests that amyloid clearance is topographically uneven, and that incomplete clearance may fail to protect against tau spread and neurodegeneration.
These findings carry meaningful implications for how we evaluate anti-amyloid therapies. If tau pathology and atrophy only slow where amyloid is extensively cleared, then partial responders may see little clinical benefit even as their PET scans improve. The geometry of the brain — gyri vs. sulci — may represent a previously underappreciated factor in treatment efficacy.
Key caveats apply: this is a single-patient case report, limiting generalizability. The TREM2 variant may alter microglial amyloid clearance dynamics in ways that don't represent the typical Alzheimer's patient. Summary is based on the abstract only.
Key Findings
- Brain regions with extensive amyloid clearance after aducanumab showed significantly less tau pathology at autopsy.
- Amyloid-cleared regions had significantly slower cortical atrophy on MRI (β = -0.50, p < .001) vs. untreated controls.
- Amyloid clearance was preferentially located in gyral crests; sulcal depths retained high amyloid and normal tau burden.
- Incomplete or patchy amyloid clearance may provide little neuroprotective benefit against downstream tau spread.
- Findings suggest full amyloid removal — not just partial reduction — may be required for clinical benefit.
Methodology
This is a clinicopathologic case report from a single academic memory center involving one male TREM2 p.R47H carrier treated with aducanumab, compared to 14 age- and genotype-matched untreated controls. Outcomes included postmortem neuropathologic evaluation, amyloid and tau PET imaging, and longitudinal MRI cortical thickness measurements.
Study Limitations
This is a single-patient case report, severely limiting statistical power and generalizability to the broader Alzheimer's population. The patient carried a rare TREM2 variant that alters microglial function and may affect amyloid clearance in atypical ways. The full manuscript was not available; this summary is based on the abstract only.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: